Group 1 - Roche Diagnostics is a global leader in the diagnostics field and has established its largest single investment project in China in Suzhou, which is the Asia-Pacific reagent and instrument production and R&D base. The annual output value of the Suzhou base is expected to reach 10 billion yuan [1] - The local government representatives expressed gratitude for Roche Diagnostics' investment in Suzhou, highlighting the city's commitment to new industrialization and the integration of technology and industry innovation [1] - Roche Diagnostics has continuously increased its investment and launched a series of innovative products since its establishment in Suzhou, contributing to mutual success between the company and the local area [1] Group 2 - Rachel Klein, Global Operations President of Roche Diagnostics, expressed appreciation for the support from Suzhou and emphasized that Roche has become an indispensable part of the global layout of Roche Group over the past ten years [2] - The company is optimistic about the future development of Suzhou and plans to continue expanding its investment and accelerate the localization of R&D and production [2]

Group 1 - Wall Street analysts expect Revvity (RVTY) to report quarterly earnings of $1.14 per share, reflecting a year-over-year decline of 6.6% [1] - Revenues are anticipated to be $711.27 million, which represents a 2.8% increase from the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the past 30 days, indicating a reassessment of projections by covering analysts [1] Group 2 - Analysts project 'Net Sales- Life Sciences' to reach $342.32 million, indicating a year-over-year increase of 9.1% [4] - The estimate for 'Net Sales- Diagnostics' is $365.99 million, reflecting a decline of 3.2% compared to the prior year [4] - Organic revenue growth for Diagnostics is expected to be 3.8%, up from 3.0% reported in the same quarter last year [5] Group 3 - Revvity shares have experienced a return of -0.3% over the past month, while the Zacks S&P 500 composite has increased by 5.9% [5] - Based on its Zacks Rank 3 (Hold), RVTY is expected to perform in line with the overall market in the near future [5]